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Background. In this prospective randomised study, the staged mucosal advancement ﬂap is compared with staged ﬁbrin sealant
application inthetreatment ofperianal ﬁstulas.Methods.Allpatientswithhighcomplexcryptoglandular ﬁstulaswererandomised
to closure of the internal opening by a mucosal advancement ﬂap (MF) or injection with ﬁbrin sealant (FS) after treatment with
setons. Recurrence rate and incontinence disorders were explored. Results. The MF group (5 females and 10 males) with a median
age of 51 years and a median followup of 52 months. The FS group (4 females and 11 males) with a median age of 45 years and a
medianfollowupof49months.Three(20%)patientsoftheMFgrouphadarecurrentﬁstulacomparedto9(60%)oftheFSgroup
(P = 0.03). No new continence disorders developed. Conclusion. Staged FS injection has a much lower success rate compared to
MF.
1.Introduction
Complex ﬁstulas are deﬁned as trans-, inter-, extra- and su-
prasphincteric ﬁstulas with tracts and branching tracts trav-
ersing the middle third or upper part of the anal sphincter.
For many years, high transsphincteric ﬁstulas were treated
by a ﬁstulotomy or a cutting seton. The disadvantage of this
technique is that it increases the incidence of continence
disorderssuchasfaecalsoiling,incontinenceforgasorliquid
stool.
At present, closure of the internal opening is the standard
procedure in the treatment of high peri-anal ﬁstulas. For
this purpose, techniques such as mucosal advancement ﬂaps,
plugs, and closure with sealants have been developed [1–4].
Several reports demonstrate rates of recurrence after these
techniques between 8% and 40% [2, 4–9]. Especially com-
plex recurrent ﬁstulas with multiple tracks above the middle
third of the sphincter are diﬃcult to treat. We therefore
adopted a staged strategy, including the use of a noncutting
or draining seton in patients with complex ﬁstulas to re-
duce the associated inﬂammation before deﬁnitive surgical
treatment by a mucosal advancement ﬂap [9]. The mucosal
advancement ﬂap is a diﬃcult procedure in the treatment of
complex high peri-anal ﬁstulas. The recurrence rate is about
20–50%, and despite the fact that the anal sphincter is in
principle saved by this technique, continence disorders are
still common [2, 8, 10–12]. The procedure requires good
surgical exposure for an adequate dissected mucosal ﬂap.
Minimal invasive techniques such as ﬁbrin sealant are intro-
duced and described by several authors to achieve a better
outcome and prevent continence disorders after treatment
[13–17]. Some authors demonstrated fewer recurrences and
no complications after repeated injections of ﬁbrin sealant
[14, 15, 17]. They suggested that this was due to the fact that
this technique is less invasive and leads to less damage of the
anal sphincter.
In this study, we compared the rate of recurrence and
rate of continence disorders of a staged ﬁbrin sealant therapy
with the staged mucosal ﬂap (used as gold standard) for
the treatment of complex peri-anal ﬁstulas in a prospective
randomised study.
2. Patients andMethods
Between 2005 and 2006, 30 consecutive patients with com-
plex peri-anal ﬁstula were surgically treated and included in2 Gastroenterology Research and Practice
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Figure 1: Flow chart of patients with perianal ﬁstulas treated in the Academic Hospital of Maastricht between 2005 and 2006.
this study (Figure 1). The Academic hospital of Maastricht is
a tertiary referral center for patients with complex perianal
ﬁstulas. Complex ﬁstulas were deﬁned as transsphincteric,
suprasphincteric, and extrasphincteric ﬁstula tracts origi-
nating from the middle third or upper part of the anal
sphincter.
The study protocol was approved by the ethical commit-
tee. Written informed consent was obtained before the start
ofthestudytocontinuefollowupattheoutpatientclinicafter
healing of the ﬁstula. All patients underwent physical exam-
ination and laboratory tests. Preoperatively, the patient’s
complaints of incontinence and soiling were recorded.
Deﬁnitive categorisation of the ﬁstula was determined by
careful examination of the MRI by the surgeon and the radi-
ologist. Patient characteristics, like age, sex, ﬁstula type, and
previoussurgicalattempts,wererecorded.Onlypatientswith
peri-anal ﬁstulas of cryptoglandular origin were included.
Female patients with rectovaginal ﬁstulas were excluded.
Patients with Crohn’s disease, patients younger than 18,
patients with malignancy or HIV were excluded.
2.1. Procedure. All patients were examined under general or
spinal anesthesia, and setons were placed. The MRI scan was
used to ﬁnd the ﬁstula tracts and their complex branches
and abscesses adjacent to and connecting with the ﬁstulae.
During seton placement residual abscesses were carefully
drained while preserving the surrounding healthy tissues as
well as possible, if there was an extra opening (internal or
external), they were managed by seton (double seton place-
ment) (Figure 3).
At least 3 months after initial treatment a second ex-
amination was carried out under general anaesthesia. After
induction of spinal or general anaesthesia, 2200mg amoxi-
cilline/clavulanate acid was given intravenously. When there
was no inﬂammatory activity at the internal opening of the
ﬁstula,
the seton was removed and deﬁnitive surgery in the form
of a mucosal advancement ﬂap (MF) [1, 2]o raﬁ b ri ns e a l a n t
injection (FS) (Figure 4)o ft h et r a c kw a sp e r f o r m e da f t e r
curettage with a sharp spoon to remove debris and granu-





























Figure 2: (a) Treatment of patients with recurrent ﬁstulas after MF. (b) Treatment of patients with recurrent ﬁstulas after FS.
2.2. Randomisation, Stratiﬁcation, and Intention to Treat.
Smoking very likely has a negative inﬂuence on the recur-
r e n c er a t ea n do no u t c o m e[ 5, 18, 19]. During the second
examination under spinal or general anaesthesia, patients
who smoked were stratiﬁed before randomisation to MF or
FS. Randomisation took place by drawing envelopes after a
telephonecalltothesecretaryduringthesecondexamination
before deﬁnitive surgery.
Evaluation of the results was carried out according to
the intention to treat principle. For instance, ﬁstulotomy had
to be performed in case of distal migration of the seton to
the lower third of the anal sphincter. When there was still
infectious activity around the ﬁstula(s) and drainage of pus
after ﬁnger compression at both sites, the surgical drainage
procedure was repeated by placing (a) new seton(s). These
patients were therefore not treated according to the research
protocol but were kept in the original randomization and are
evaluated as such. In case of persisting infection, a new MRI
scanwasmade afterat least6weeks beforeathird lookunder
general anaesthesia was performed.
2.3. Examination. Patients were followed at regular intervals
ofthreemonthsattheoutpatientclinicandwerereexamined
for the purpose of this study. The ﬁstula was considered to
be healed if there was no drainage of the previous external
opening with and without ﬁnger compression and when
the external ﬁstula oriﬁce(s) was healed and asymptomatic.
Special attention was paid to the presence of recurrent
ﬁstulas. If there was any doubt regarding the presence of a
recurrent ﬁstula tract, an MRI was performed. A “recurrent”
ﬁstula, absence of wound healing, and persistent symptoms
within 3 months after deﬁnitive treatment were deﬁned as4 Gastroenterology Research and Practice
Figure 3: An example of double seton placement in an extra exter-
nal opening.
a failure of treatment. Continence disorders were scored
by the Vaizey incontinence score before treatment and at
6 and 12 months after treatment. Before treatment and at
6 and 12 months after treatment, the patients ﬁlled in a
KEA quality-of-life questionnaire, a EuroQol-5D instrument
which evaluates ﬁve health domains: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression in
relation to faecal incontinence [20].
2.4. Statistical Analysis. A recurrent ﬁstula and incontinence
disorder were used as a combined clinical endpoint, the out-
comeoftheKEAquality-of-lifescorewasusedasasecondary
endpoint. The followup of the patients was stated at least 24
months.
The recurrence rate and percentage of incontinence
disorders of treatment by a mucosal ﬂap are 25% and 30%,
respectively [5, 8, 9]. Power analysis was based on an expect-
ed reduction of 50% of incontinence disorders and the same
recurrence outcome in the FS group compared to the MF
group. Two groups of 80 patients could have been included
in approximately two years.
Statistical analysis included two-tailed T tests, two-way
analysis for the observed changes in the faecal incontinence
quality-of-life scales. For comparison between the MF group
and FS group, chi-square analysis and the Fisher’s exact test
was used. A probability of 0.05 was considered signiﬁcant.
3. Results
This study is stopped after the inclusion of 30 patients
because of the unacceptable results of the ﬁbrin glue. All
patients stayed in followup. After termination of the study,
one patient treated with staged ﬁbrin sealant had a recurrent
ﬁstula.
3.1. Staged Mucosal Advancement Flap. Ten men and 5
women with a median age of 51 years (range 39–70) were
treated for complex perianal ﬁstulas by seton drainage fol-
lowed by a mucosal advancement ﬂap (MF). The median
Figure 4: Injection of ﬁbrin sealant injection (FS) after the seton
w a sr e m o v e da n dc u r e t t e dw i t has h a r ps p o o n .
followup after deﬁnitive treatment was 52 months (range
26–60). The median interval between seton placement and
deﬁnitive surgical procedure was 4 months (range 3–15).
Six patients were smoking during treatment. The patient
characteristics are described in Table 1. Eleven patients
(73%) had 2 or more high ﬁstula tracts, and 4 patients
(27%) had one high ﬁstula tract detected on MRI. In only 2
patients (13%), an abscess was found on MRI and drained
after exploration under general or spinal anaesthesia. In 3
(20%) patients, residual inﬂammatory activity was seen on
MRI (Table 1).
Two patients already suﬀered from faecal soiling pre-
operatively, which was unchanged after treatment. No new
continence disorders developed after deﬁnitive treatment in
the other patients. Three (20%) patients developed a recur-
rent ﬁstula. A new staged mucosal advancement ﬂap was
successfully done in all 3 patients without complications
(Figure 2).
3.2. Staged Fibrin Sealant Treatment. Eleven men and 4
women with a median age of 45 years (range 30–68) were
treated for complex peri-anal ﬁstulas by seton drainage
followed by ﬁbrin sealant (FS). The median duration of
followup after deﬁnitive treatment was 49 months (range
29–59). The median interval between seton placement and
the deﬁnitive surgical procedure was 4 months (range 3–14).
Eight patients were smokers during treatment. The patient
characteristics are described in Table 1. Ten patients (67%)
had two or more high ﬁstula tracts, and ﬁve patients (33%)
had one high ﬁstula tract seen on MRI. In none of the
patients,anabscesswasdetectedonMRI.In4(26%)patients
residual inﬂammation was found on MRI (Table 1).
Three patients suﬀered from faecal soiling preoperatively
which remained unchanged after treatment. No new conti-
nence disorders developed after deﬁnitive treatment in the
other patients. Nine (60%) patients developed a recurrent
ﬁstula. In 3 patients, a new staged ﬁbrin sealant treatment
was performed. In only one patient the repeated treatment
was successful. The treatment characteristics are described in
Figure 2.Gastroenterology Research and Practice 5
Table 1: (a) Patient characteristics of the ﬁstula. (b) patient characteristics.
(a)
MF FS
N = 15 N = 15
1ﬁ s t u l at r a c k N = 4 (27%) N = 10 (67%) P = 0.15
2 or more ﬁstula tracks N = 11 (73%) N = 5 (33%) P = 0.08
Abscess N = 2 (13%) N = 0 (0%) P = 0.20
Residual inﬂammation and prolonged seton treatment N = 3 (20%) N = 4 (27%) P = 0.30
(b)
MF FS
N = 15 N = 15
Sex Male N = 10 (67%) Male N = 11 (73%) P = 0.55
Female N = 5 (33%) Female N = 4 (27%)
Age (years) 51 (range 39–70) 45 (range 30–68) P = 0.48
Median followup (months) 52 (46–60) months 49 (49–59) months P = 0.45
Tobacco smokers N = 6 (40%) N = 8 (53%) P = 0.30
Soiling (before treatment) N = 2 (13%) N = 3 (20%) P = 0.40
Table 2: Table Patients outcome.
MF FS
N = 15 N = 15
Failure of treatment N = 0 N = 0
Recurrent ﬁstula N = 3 (20%) N = 9 (60%) P = 0.03
Soiling after treatment N = 0 N = 0
Recurrent ﬁstula
In tobacco smokers
(N = 6) (N = 8) P = 0.000
N = 1 (17%) N = 8 (100%)
Median quality-of-life score:
Before treatment 85 87 P = 0.32
After 6 months 86 90 P = 0.44
After 12 months 87 84 P = 0.50
Vaizey incontinence score
Before treatment 0.50 (0–4) 0.73 (0–4) P = 0.76
After 6 months 0.50 (0–4) 0.73 (0–4) P = 0.76
After 12 months 0.50 (0–4) 0.73 (0–4) P = 0.76
3.3. Comparison Between Groups (Table 2). Three patients
(20%) of the MF group and 9 (60%) of the FS group
developed a recurrent ﬁstula (P = 0.06). Nine (64%) of
all the smoking patients (n = 14) and 3 (18%) of the no-
smoking patients (n = 16) had a recurrent ﬁstula (P = 0.02).
Eight patients (100%) of the tobacco smokers developed
a recurrent ﬁstula in the FS group, and one patient (17%) of
the tobacco smokers developed a recurrent ﬁstula in the MF
group (P<0.001).
No diﬀerence in quality of life (EuroQuol-5D) was found
6 and 12 months after treatment between both groups.
Previous surgical attempts, sex, and age were not associated
with outcome in both groups.
In this study, no distal migration of the seton, enabling
simple ﬁstulotomy, was found.
4. Discussion
Low inﬂammatory activity at the site of the ﬁstula may
provide a better chance of deﬁnitive cure by ultimate surgical
treatment. In a previous study, we have shown that a recur-
rence rate of 22% can be achieved if the mucosal advance-
mentﬂapis precededbyatleast3months setondrainage[9].
The present study shows a less favourable result for staged
ﬁbrin sealant treatment. Healing of a high ﬁstula requires
adequate closure of the internal opening, which may not be
achieved with ﬁbrin sealant. The length of time of adequate
sealing of the curetted ﬁstula track by ﬁbrin sealant is prob-
ably too short to allow successful formation of a deﬁnitive
scaﬀold to close the internal opening. Buchanan et al. could
not ﬁnd remaining traces of ﬁbrin sealant microscopically as6 Gastroenterology Research and Practice
earlyastwoweeksafterinjection[21].Otherstudiesreported
high recurrence rates from 40% up to 86% after treatment
with ﬁbrin sealant with or without repeated injections in low
as well as in high peri-anal ﬁstulas [14, 17, 22, 23]. Lindsey
et al. found a recurrence rate of 31% in complex ﬁstulas
and 50% in low ﬁstulas treated with ﬁbrin sealant [13]. But
they all reported no continence disorders and described the
injection of ﬁbrin sealant as an easy technique [13,14,17,22,
23].Alexanderetal.alsofoundadverseeﬀects,likeprolonged
severe pain, discharge of great amounts of purulent liquid
from the external opening, and abscess formation of ﬁbrin
sealant in transanal advancement ﬂap repair [24].
Zimmerman et al. reported that tobacco smokers treated
for peri-anal ﬁstulas with transanal advancement ﬂap repair
have a 20% higher recurrence rate compared to patients
without a smoking habit [5]. They suggested that a nicotine
induced decrease in rectal mucosal perfusion contributes to
the breakdown of the advancement ﬂap [18]. Our study
shows an even greater negative impact of smoking on the
success of staged ﬁbrin sealant treatment compared to the
staged mucosal advancement ﬂap. This suggests that smok-
ing always aﬀects the outcome of peri-anal ﬁstula repair
but especially in inferior treatment modalities. Smoking is
also a risk factor for wound healing in perineal wounds
[25, 26]. Closure of the internal opening occurs following
the general principles of wound healing. A mucosal defect
exists which needs to be bridged by inﬂux of white cells,
macrophages, ﬁbroblasts, and proteins, all together leading
totheformationofascaﬀoldforfurthertissuerepair,includ-
ing deposition of collagen, ﬁbrous tissue, and capillarization.
It can be assumed that mucosal advancement techniques
potentially allowprimary woundclosure,whileﬁbrinsealant
only accelerates scaﬀold formation, after which secondary
woundhealingandepithelialisationarenecessary.Secondary
wound healing requires more of the intrinsic healing poten-
tial of the tissue than primary repair. Smoking is known
to interfere with many of the stages in wound healing. The
synthesis of collagen in smokers is impeded [27]. Nicotine is
a vasoconstrictor that reduces the nutritional blood ﬂow to
the wound. The proliferation of red blood cells, ﬁbroblasts,
and macrophages is reduced by nicotine. Oxygen transport
and metabolism is diminished by carbon monoxide and
hydrogen cyanide inhibits enzyme systems necessary for the
oxidative metabolism and transport at cellular level. The
negative inﬂuence on wound repair is of particular concern
in plastic and reconstructive surgery. Because of the obvious
correlationbetweenthenumberofcigarettessmokedandthe
healing rate of the wound patients should be advised to quit
smoking at least a month before performing elective surgery
[28].
5. Conclusions
Based on the results of the present study, it is concluded
that a staged ﬁbrin sealant injection has a lower success rate
compared to a staged mucosal advancement ﬂap, especially
in patients that smoke. However, after the drawback of this
study, thenumber ofpatients in bothgroupsissmall.Butthe
results of treatment with ﬁbrin sealant after seton placement
are unacceptable. Although the staged mucosal advancement
ﬂap is a technically more demanding procedure compared to
the injection of ﬁbrin sealant, the complication rate is low
for both procedures in the hands of dedicated surgeons. In
this and another study, a repeated ﬁbrin sealant injection
in patients with a recurrent ﬁstula has a lower healing rate
and thus requires more procedures compared to a repeated
staged mucosal ﬂap [29]. Moreover because ﬁbrin sealant is
expensive, a repeated staged mucosal ﬂap is a better choice in
patients with recurrent perianal ﬁstulas.
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